A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014

A. Messersmith, Wells; I. Shapiro, Geoffrey; M. Cleary, James; Jimeno, Antonio; Dasari, Arvind; Huang, Bo; Naveed Shaik, M.; Cesari, Rossano; Zheng, Xianxian; M. Reynolds, Jennifer; A. English, Patricia; R. McLachlan, Karen; A. Kern, Kenneth; LoRusso, Patricia

doi:10.1158/1078-0432.ccr-14-0607

Public

A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014

Published in Clinical Cancer Research • Sep 18, 2014

Authors:

Wells A. Messersmith

Geoffrey I. Shapiro

James M. Cleary

Abstract

PURPOSE: To estimate the maximum tolerated dose (MTD) for continuous oral administration of the γ-secretase inhibitor PF-03084014, determine the recommended phase II dose (RP2D), and evaluate safety and preliminary activity in patients with advanced solid tumors. EXPERIMENTAL DESIGN: This open-label...

Subject

Medicine

Nausea

Rash

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!